Lysosomal Storage Diseases Market by Disease Type (Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis), Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), End User - Global Forecast 2024-2030

Lysosomal Storage Diseases Market by Disease Type (Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis), Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), End User - Global Forecast 2024-2030


The Lysosomal Storage Diseases Market size was estimated at USD 9.31 billion in 2023 and expected to reach USD 9.98 billion in 2024, at a CAGR 7.48% to reach USD 15.43 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Lysosomal Storage Diseases Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Lysosomal Storage Diseases Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Lysosomal Storage Diseases Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, ArmaGen, Inc., BioMarin, CHIESI USA, Inc., Denali Therapeutics Inc., Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co., Ltd., Lysogene, Neurogene Inc., Novartis AG, Orchard Therapeutics Limited, Pfizer Inc., Protalix, Sangamo Therapeutics, Inc., Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, and Ultragenyx Pharmaceutical Inc..

Market Segmentation & Coverage

This research report categorizes the Lysosomal Storage Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

Disease Type

Fabry Diseases

Gaucher's Diseases

Mucopolysaccharidosis

Pompe's Syndrome
Type of Therapy

Enzyme Replacement Therapy

Stem Cell Therapy

Substrate Reduction Therapy
End User

Clinics

Hospitals
Region

Americas
Argentina
Brazil
Canada
Mexico
United States

California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas

Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Lysosomal Storage Diseases Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Lysosomal Storage Diseases Market?
3. What are the technology trends and regulatory frameworks in the Lysosomal Storage Diseases Market?
4. What is the market share of the leading vendors in the Lysosomal Storage Diseases Market?
5. Which modes and strategic moves are suitable for entering the Lysosomal Storage Diseases Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Lysosomal Storage Diseases Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of lysosomal storage disorders worldwide
5.1.1.2. Inclination toward early diagnosis and treatment of diseases
5.1.1.3. Increasing use of enzyme replacement therapies
5.1.2. Restraints
5.1.2.1. High cost associated with the treatment of t lysosomal storage disease
5.1.3. Opportunities
5.1.3.1. Advancements in gene editing technologies and gene therapies
5.1.3.2. Emergence of personalized medicine approach to treat lysosomal storage conditions
5.1.4. Challenges
5.1.4.1. Stringent regulatory framework for approval of lysosomal storage drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Lysosomal Storage Diseases Market, by Disease Type
6.1. Introduction
6.2. Fabry Diseases
6.3. Gaucher's Diseases
6.4. Mucopolysaccharidosis
6.5. Pompe's Syndrome
7. Lysosomal Storage Diseases Market, by Type of Therapy
7.1. Introduction
7.2. Enzyme Replacement Therapy
7.3. Stem Cell Therapy
7.4. Substrate Reduction Therapy
8. Lysosomal Storage Diseases Market, by End User
8.1. Introduction
8.2. Clinics
8.3. Hospitals
9. Americas Lysosomal Storage Diseases Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Lysosomal Storage Diseases Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Lysosomal Storage Diseases Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Abeona Therapeutics Inc.
13.1.2. Alexion Pharmaceuticals, Inc.
13.1.3. Amicus Therapeutics
13.1.4. ArmaGen, Inc.
13.1.5. BioMarin
13.1.6. CHIESI USA, Inc.
13.1.7. Denali Therapeutics Inc.
13.1.8. Freeline Therapeutics
13.1.9. Homology Medicines, Inc.
13.1.10. Horizon Pharma PLC
13.1.11. Idorsia Pharmaceuticals Ltd.
13.1.12. JCR Pharmaceuticals Co., Ltd.
13.1.13. Lysogene
13.1.14. Neurogene Inc.
13.1.15. Novartis AG
13.1.16. Orchard Therapeutics Limited
13.1.17. Pfizer Inc.
13.1.18. Protalix
13.1.19. Sangamo Therapeutics, Inc.
13.1.20. Sanofi S.A.
13.1.21. Spark Therapeutics, Inc.
13.1.22. Swedish Orphan Biovitrum AB
13.1.23. Takeda Pharmaceutical Company Limited
13.1.24. Ultragenyx Pharmaceutical Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
FIGURE 1. LYSOSOMAL STORAGE DISEASES MARKET RESEARCH PROCESS
FIGURE 2. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2023 VS 2030
FIGURE 3. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. LYSOSOMAL STORAGE DISEASES MARKET DYNAMICS
FIGURE 7. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 8. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
FIGURE 10. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 12. LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings